+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032- Product Image
Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032- Product Image
New

Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5181418
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Healthcare-associated Infectious Disease Diagnostics Market is undergoing significant transformation as healthcare demands evolve and new technologies reshape clinical and operational priorities. Growing pressure for evidence-based patient management is accelerating adoption of advanced infectious disease diagnostics within hospitals, outpatient centers, and community settings.

Market Snapshot

In 2025, the Healthcare-associated Infectious Disease Diagnostics Market achieved a value of USD 27.66 billion and is projected to reach USD 29.82 billion in 2026, representing sustained momentum across global healthcare sectors. The market is forecasted to expand at a compound annual growth rate (CAGR) of 8.75%, with expectations to reach USD 49.77 billion by 2032. Digitalization, innovation in molecular and immunoassay technologies, and evolving healthcare delivery models are key drivers in this growth trajectory.

Scope & Segmentation

This report provides in-depth analysis across the Healthcare-associated Infectious Disease Diagnostics landscape, encompassing critical technologies, regional differences, and stakeholder strategies.

  • Test Methods: Includes immunoassays (such as chemiluminescent immunoassays, ELISA, lateral flow assays), microbiology (aerobic/anaerobic culture, microscopy, sensitivity testing), and molecular diagnostics (isothermal amplification, PCR, sequencing).
  • Pathogen Types: Evaluates diagnostic priorities for bacterial (e.g., Clostridium difficile, Escherichia coli, Staphylococcus aureus), fungal (Aspergillus, Candida, Cryptococcus neoformans), parasitic (malaria, Toxoplasma gondii), and viral agents (coronaviruses, influenza, norovirus, RSV).
  • End Users: Examines diagnostic laboratories, hospitals (clinical pathology and microbiology), and point-of-care venues (clinics, emergency departments, long-term care).
  • Sample Modalities: Covers blood (serum, whole blood), cerebrospinal fluid, respiratory specimens, urine (catheterized, midstream), and wound swabs.
  • Regions: Analyzes adoption and procurement trends across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Additional focus areas include procurement pathways, diagnostic validation processes, and clinical workflow integration.

Key Takeaways

  • Rapid pathogen identification is directly shaping clinical decision-making, antimicrobial stewardship, and infection control, with increased prioritization of real-time results.
  • Technological advances, including improved molecular and immunoassay platforms, are enabling a shift from centralized laboratory models toward more accessible near-patient testing.
  • Clinical practices now favor integrated diagnostic strategies, combining rapid molecular results with confirmatory culture and susceptibility data for optimal patient management.
  • Procurement dynamics increasingly require flexibility as vendor relationships, supply chain resilience, and operational workflows adjust to new demand patterns and emerging cost pressures.
  • Segmented needs by test method, sample type, and end user drive development priorities, encouraging product flexibility and evidence generation that targets a range of healthcare environments.
  • Regional variation in healthcare infrastructure, regulatory frameworks, and surveillance requirements necessitates customized approaches to deployment, reimbursement, and commercialization.

Tariff Impact: Strategic Implications

Recent tariff adjustments in the United States introduce new challenges for diagnostics manufacturers and health systems. Changes to import costs for instruments, reagents, and consumables compel manufacturers to rethink sourcing strategies and inventory policies. Hospitals and procurement leaders are increasingly attentive to cost control, supply chain diversification, and mitigation of tariff risk. These operational considerations are influencing technology platform selection and may drive adoption of regionally manufactured solutions or multi-vendor strategies. Payers and regulators are monitoring tariff-related impacts on value-based purchasing, potentially affecting future reimbursement mechanisms and procurement guidelines.

Methodology & Data Sources

This analysis integrates systematic literature reviews, stakeholder interviews, and triangulation of technical and regulatory documents. Clinicians, laboratory directors, procurement officers, and industry executives contributed insights on operational needs and technology preferences. Data cross-validation ensured reliability and transparency in findings and recommendations.

Why This Report Matters

  • Delivers actionable insights for strategic planning in product development, procurement, and commercialization for diagnostic manufacturers and healthcare leaders.
  • Clarifies evolving dynamics in infection detection, regulatory adaptation, and market segmentation to support informed decision-making in complex regional environments.
  • Supports alignment of technology innovation and operational feasibility, underpinning value-driven diagnostic adoption for improved patient care outcomes.

Conclusion

The convergence of clinical demand, regulatory change, and technological progress is redefining infectious disease diagnostics. Success requires coordinated approaches, resilient supply strategies, and adaptive technology deployment to achieve measurable clinical and operational impact across healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method
8.1. Immunoassays
8.1.1. Chemiluminescent Immunoassay
8.1.2. ELISA
8.1.3. Lateral Flow Assays
8.2. Microbiology
8.2.1. Culture
8.2.1.1. Aerobic Culture
8.2.1.2. Anaerobic Culture
8.2.2. Microscopy
8.2.3. Sensitivity Testing
8.3. Molecular Diagnostics
8.3.1. Isothermal Amplification
8.3.2. PCR
8.3.3. Sequencing
9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type
9.1. Bacterial
9.1.1. Clostridium Difficile
9.1.2. Escherichia Coli
9.1.3. Pseudomonas Aeruginosa
9.1.4. Staphylococcus Aureus
9.2. Fungal
9.2.1. Aspergillus Species
9.2.2. Candida Species
9.2.3. Cryptococcus Neoformans
9.3. Parasitic
9.3.1. Malaria Parasites
9.3.2. Toxoplasma Gondii
9.4. Viral
9.4.1. Coronavirus
9.4.2. Influenza Virus
9.4.3. Norovirus
9.4.4. Respiratory Syncytial Virus
10. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type
10.1. Blood
10.1.1. Serum
10.1.2. Whole Blood
10.2. Cerebrospinal Fluid
10.3. Respiratory
10.3.1. Bronchoalveolar Lavage
10.3.2. Nasopharyngeal Swabs
10.3.3. Sputum
10.4. Urine
10.4.1. Catheterized Urine
10.4.2. Midstream Urine
10.5. Wound Swabs
10.5.1. Deep Tissue Samples
10.5.2. Surface Swabs
11. Healthcare-associated Infectious Disease Diagnostics Market, by End User
11.1. Diagnostic Laboratories
11.1.1. Independent Laboratories
11.1.2. Reference Laboratories
11.2. Hospitals
11.2.1. Clinical Pathology Laboratories
11.2.2. Microbiology Laboratories
11.3. Point Of Care
11.3.1. Clinics
11.3.2. Emergency Departments
11.3.3. Long Term Care Facilities
12. Healthcare-associated Infectious Disease Diagnostics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Healthcare-associated Infectious Disease Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Healthcare-associated Infectious Disease Diagnostics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Healthcare-associated Infectious Disease Diagnostics Market
16. China Healthcare-associated Infectious Disease Diagnostics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Becton, Dickinson and Company
17.7. Bio-Rad Laboratories, Inc.
17.8. bioMérieux SA
17.9. Danaher Corporation
17.10. DiaSorin S.p.A.
17.11. QIAGEN N.V.
17.12. Roche Diagnostics International AG
17.13. Siemens Healthineers AG
17.14. Sysmex Corporation
17.15. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 187. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 188. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
TABLE 189. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 190. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
TABLE 191. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
TABLE 192. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 193. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 194. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 195. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
TABLE 196. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
TABLE 197. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 198. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 199. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 200. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
TABLE 201. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
TABLE 202. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
TABLE 203. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 205. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 206. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
TABLE 211. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
TABLE 212. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 213. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 214. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 215. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
TABLE 216. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
TABLE 217. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 218. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 219. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 220. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
TABLE 221. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
TABLE 222. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
TABLE 223. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
TABLE 225. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 226. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
TABLE 229. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 230. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
TABLE 231. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
TABLE 232. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 233. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 234. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 235. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
TABLE 236. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
TABLE 237. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 238. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 239. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 240. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
TABLE 241. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
TABLE 242. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
TABLE 243. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032

Companies Mentioned

The key companies profiled in this Healthcare-associated Infectious Disease Diagnostics market report include:
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • DiaSorin S.p.A.
  • QIAGEN N.V.
  • Roche Diagnostics International AG
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 29.82 Billion
Forecasted Market Value ( USD ) by 2032 $ 49.77 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Hospital Acquired Infections Testing Kits Market Report 2025 - Product Image

Hospital Acquired Infections Testing Kits Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test (Molecular, Conventional), Infection (UTI, Pneumonia), Product, Type, and Region with Growth Forecasts, 2025-2030 - Product Image

Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test (Molecular, Conventional), Infection (UTI, Pneumonia), Product, Type, and Region with Growth Forecasts, 2025-2030

  • Report
  • 70 Pages
  • Global
From
Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033 - Product Image

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From
Infectious Disease Diagnostic Market - Global Forecast 2026-2032 - Product Image

Infectious Disease Diagnostic Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From

About the Hospital Acquired Infection Diagnostics Market

The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics. The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection. Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.